Clinical Trial Update: A Study of VRd-based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple Myeloma [Phase 2]

View source ↗

Summary

Clinical trial update for a Phase 2 study evaluating a VRd-based regimen followed by BCMA CAR-T therapy in transplant-ineligible patients with newly diagnosed m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• BCMA CAR-T therapy (BCMA-targeted chimeric antigen receptor T-cell therapy)
• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Multiple Myeloma | Phase 2 | Status: ACTIVE_NOT_RECRUITING